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OBJECTIVES: The aim of the present study was to assess the diagnostic 
delay and the associated factors in patients with cutaneous malignant mela-
noma. METHODS: We carried out a survey including medical record analysis in 
patients diagnosed within five years with cutaneous malignant melanoma at the 
Pécs Dermatological Clinic (n= 362).The study investigated the diagnostic delay, its 
risk factors as clinical and histological characteristics of the tumor, and patients’ 
sociodemographic factors. Chi-square test, Mann-Whitney U test, and Kruskall-
Vallis test was used with 95% probability level (p< 0.05). RESULTS: 195 females and 
167 males participated in the investigation. The mean age was 54.5+/-14.8. Breslow 
tumor thickness was below 1 mm in 48.1% of patients and above 4 mm in 12.2% of 
patients. 35.1% of patients consulted a doctors six or more months later than the 
symptoms had appeared. The mean delay was 8.1+/-15.6 months. The prolonged 
delay resulted in more expressed tumor thickness (p= 0.027). Tumor thickness and 
delay showed no significant difference in the case of the tumor type and ulceration 
(p> 0.05). A higher proportion of women discovered the abnormality compared with 
men (65.2% versus 34.8%; p< 0.001). The latter subjects were informed by their rela-
tives to examine themselves. The most common site of prevalence was the lower 
limb in females (78.5% of cases); the trunk in males (61.3% of cases) (p< 0.001). 
The most common symptom observed by patients was the increase in lesion 
size (50.3%). Its prevalence on the lower limb (p= 0.01) and the increase in lesion 
size (p< 0.001) was associated with significantly longer delay. CONCLUSIONS: 
The study provides essential information for developing education campaigns in 
the future involving awareness promotion related to lesions perceived as minor 
significance. The present study emphasizes the importance of mindfulness and 
skills in the early detection of tumors. Prevention should be a decisive factor in 
primary care.
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OBJECTIVES: To evaluate measurement properties of the Psoriasis Symptom 
Inventory (PSI) in moderate/severe plaque psoriasis (PsO). METHODS: A second-
ary analysis of pooled data from a Phase III study of brodalumab in moderate to 
severe PsO patients (n= 661) was conducted. Outcome measures included: PSI (as 
a daily electronic diary), Psoriasis Area and Severity Index (PASI), static Physician’s 
Global Assessment (sPGA), involved body surface area (BSA), Dermatology Life 
Quality Index (DLQI), and the 36-item Health Survey version 2 (SF-36v2). Analyses 
included: confirmatory factor analysis (CFA) and Rasch analysis (dimensionality 
and item performance); Cronbach’s α (internal consistency); intraclass correla-
tion coefficients (ICCs) among patients with stable disease (test-retest reliabil-
ity); Spearman correlations (convergent validity); analysis of variance (known 
groups validity and ability to detect change); and agreement (Kappa, k) between 
PSI responders (PSI total score≤ 8 with no item score> 1) and PASI 75/90, sPGA 
0/1, and DLQI 0/1 responders. RESULTS: Results supported unidimensionality, 
good item fit, ordered responses, and combining of items into a single total score. 
Cronbach’s α s were ≥ 0.92 at baseline. Test-retest ICCs were ≥ 0.95 (week 6 to 8). 
At baseline, moderate/strong correlations between PSI total score and DLQI item 1 
(skin symptoms; r= 0.69), DLQI symptoms and feelings domain (r= 0.66), and SF-36 
bodily pain (r= -0.58) supported convergent validity. PSI scores were significantly 
different (p< 0.001) among known PsO severity groups based on PASI (< 12 or ≥ 12), 
sPGA (0–1, 2–3, or 4–5), BSA (< 5, 5-10, or > 10), and DLQI (≤ 5 or > 5) at week 8 and 
12. At week 12, the PSI detected significant changes in PsO severity based on PASI 
(< 50; 50< 75; ≥ 75) and sPGA (0/1; ≥ 2), and showed good agreement (k≥ 0.66) between 
PSI response and PASI, sPGA, and DLQI responses. CONCLUSIONS: The PSI dem-
onstrated excellent reliability, validity, and ability to detect change in severity of 
psoriasis signs and symptoms.
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OBJECTIVES: Patients with Hidradenitis Suppurativa (HS) experience painful 
abscesses and nodules primarily in the skin flexures, along with other disease-
related impact and symptoms, which can further diminish their health-related 
quality of life. No HS-specific tools exist to assess those symptoms and impacts. 
We aimed to report the development and initial psychometric evaluation of the 
Hidradenitis Suppurativa Symptom Assessment (HSSA) and the Hidradenitis 
Suppurativa Impact Assessment (HSIA). METHODS: The HSSA and HSIA were 
developed based on a literature review and concept elicitation interviews with 
HS patients (n= 20). Following initial construction, the questionnaires were cog-
nitively debriefed among HS patients (n= 20) to test their readability and com-
prehensiveness. Next, the HSIA and HSSA were implemented in a multi-center, 
non-interventional study with HS patients (n= 40) to evaluate their item and scale 
OBJECTIVES: Pressure ulcers (PU) are distressing events, caused when skin and 
the underlying tissues are placed under pressure sufficient to impair blood supply. 
They can have a substantial impact on quality of life, and have significant resource 
implications, with extended hospital stays and significant staff time devoted to 
treating the more severe cases. Repositioning is a key prevention strategy, but 
can be resource intensive, leading to variation in practice. This economic analysis 
formed part of the National Institute for Health and Care Excellence (NICE) clinical 
guideline on PU prevention and management, and was conducted to identify the 
most cost-effect repositioning strategy for the prevention of PU. METHODS: The 
clinical inputs to the model were taken from the systematic review of clinical data 
conducted for the guideline. The model population was elderly people in a nurs-
ing home; this represents a group at high risk of developing a PU. The economic 
model was developed in consultation with members of the guideline development 
group (GDG), and took the perspective of the UK National Health Service. Outcomes 
were expressed as costs and quality adjusted life years (QALYs). RESULTS: Despite 
being marginally more clinically effective, 2 and 4 hourly repositioning is not cost-
effective (compared to 4 hourly repositioning) for this high risk group of patients 
at a cost-effectiveness threshold of £20,000 per QALY. The ICER was £1,854,070 per 
QALY. CONCLUSIONS: 2 and 4 hourly repositioning is not cost-effective (compared 
to 4 hourly repositioning) in the UK for the group of patients analyzed here. These 
results were used to inform the guideline recommendations. FUNDING: This work 
was undertaken by the National Clinical Guideline Centre, which received funding 
from NICE. The views expressed in this publication are those of the authors and 
not necessarily of the institute.
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OBJECTIVES: To evaluate the cost-effectiveness of ranibizumab compared with 
aflibercept for the treatment of neovascular (wet) age-related macular degenera-
tion AMD from the UK healthcare provider perspective. METHODS: A patient 
simulation model was developed with best corrected visual acuity (BCVA) used 
as a marker of disease progression. Baseline patient characteristics were based 
on the EXCITE Phase III study. Change in BCVA for Year 1 and Year 2 were based 
on a network meta-analysis. Beyond Year 2 or after treatment discontinuation, 
BCVA in the treated eye was modelled using natural history data for wet AMD 
patients. Natural history data for the general population was used to model the 
untreated eye. BCVA change in each eye was modelled independently. A prob-
ability of developing bilateral disease was applied throughout the model. Utility 
values were estimated by a regression analysis of BCVA in the better-seeing 
eye (BSE) and in the worse-seeing eye (WSE). Three scenarios based on differ-
ent treatment and monitoring schedules were analyzed; pro-re-nata (PRN), treat 
and extend (T&E), observe and extend (O&E). The model assumed that 50% of 
patients were treated via one-stop monitoring, and 50% with two-stop moni-
toring. RESULTS: The difference in lifetime costs associated with ranibizumab 
(0.5mg) ranges from a saving of £22 with T&E regimen, to a reduction of £7,416 
with a PRN regimen. In addition, ranibizumab was associated with lifetime 
quality-adjusted life years (QALYs) of 5.07 compared with 5.06 for aflibercept 
and as a consequence dominated aflibercept. Probabilistic sensitivity analysis 
suggests that the probability of ranibizumab (0.5mg) being cost-effective with 
a T&E regimen is 27% at a £20,000 threshold, and 30% at a £30,000 threshold. 
With a PRN regimen, the probability of cost-effectiveness was 86% at a £20,000 
threshold and 86% at a £30,000 threshold. CONCLUSIONS: Ranibizumab domi-
nates aflibercept for patients with neovascular AMD irrespective of treatment 
regimen.
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OBJECTIVES: The World Health Organization reports that India’s rates of debili-
tating hearing loss are more than double rates in Europe and North America. 
With a population over 1.25 billion, India’s burden of hearing loss is extremely 
high. The cochlear implant (CI) is a highly effective treatment, providing some 
hearing to the deaf; however, CI use is extremely limited in India due to device 
cost, low incomes, limited medical and audiology expertise, and lack of aware-
ness. The objective of this study is to estimate the cost of a CI device whose use 
would be considered cost-effective in India for 1-year old children—the subgroup 
with the greatest utility gain. METHODS: The lifetime QALYs gained and payer 
costs are estimated based on a literature review and Indian life tables, and are 
discounted at 3% annually. The threshold incremental cost-utility ratio (ICUR) is 
considered at 3x, 2x, and 1x per capita gross domestic product (PCGDP). Given 
cost estimates of pre-implant evaluations, surgery costs, post-implant audiol-
ogy care, device upkeep, and the medical costs of complications and revision 
surgery, the ICUR equation is solved to determine the maximum cost-effective 
device cost. RESULTS: The health utility gain for a CI device implanted in a 1-year 
old was estimated at 0.36 with confidence interval (0.29; 0.43). Lifetime QALY 
gain was 9.28 (7.47; 11.03). Lifetime costs excluding the device cost were $14,895 
($10,639--$20,853). Given a PCGDP of $1,666, the cost-effectiveness willingness-
to-pay thresholds for maximum device cost for 3x, 2x and 1x PCGDP were $24,664 
($10,973; $36,664), $11,477 ($36; $20,896) and -$1,709 (-$10,242; $5,129), respec-
tively. The current minimum price of the device is ~$12,000. CONCLUSIONS: CIs 
in 1-year olds would be cost-effective in India based on a threshold of 3x or 2x 
PCGDP, but medical and device costs would have to be reduced to meet a 1x PCGDP 
threshold.
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for the databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was 
collected for the study size, interventions, year, PRO instrument and results for PROs. 
Analysis for conducted to identify trends in commonly used PRO instruments and 
categorize results as positive, neutral or negative. RESULTS: 31 studies with a total of 
9819 patients were identified. In these studies there were eleven different PROs instru-
ments were identified that were Glaucoma health perception index, Glaucoma quality 
of life questionnaire (Glau-QoL), Glaucoma utility index, Impact of vision impairment, 
Low vision quality of life questionnaire, National eye institute visual function index-
19 items, National eye institute visual function index-51 items, Nursing home vision 
quality of life questionnaire, Quality of life and visual function questionnaire, Vision 
core module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). CONCLUSIONS: Patients with glaucoma have sig-
nificant impairment in their QoL, hence collection of such data is important for new 
medical products. PRO instruments such as Impact of vision impairment and Low 
vision quality of life questionnaire have been commonly used to generate evidence 
to show which therapies improve patient QoL.
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OBJECTIVES: A recent systematic literature review of randomized controlled der-
matology-related trials showed that patient-reported efficacy outcomes (PROs) were 
mentioned in some form in only 25.6% of 125 trials between 1994 and 2001. Our 
research aimed to characterize the benefits of PROs in drug development in derma-
tology from the patient, prescriber, regulator, payer, and manufacturer perspectives 
using a case study approach. The case studies were identified based on the use of 
PROs in pivotal clinical trials for the product. METHODS: A targeted literature review 
was conducted in PubMed from 2004 to 2014 for six products (Atopiclair for atopic 
dermatitis, botulinum toxin type A for hyperhidrosis, calcipotriol plus betametha-
sone dipropionate gel for scalp psoriasis, pimecrolimus and tacrolimus for atopic 
dermatitis, and ustekinumab for psoriasis. Regulatory and health technology agency 
websites and publications were searched for documentation of PRO label claims 
and mentions. RESULTS: For patients, inclusion of PROs ensured the full benefit 
of the product was demonstrated, including improvement in symptoms, quality of 
life, and/or treatment satisfaction. For prescribers, comparative trials reported PRO 
data information on each product’s benefits and risks and also which product was 
superior from the patient perspective. For regulators, for all except one of the six 
products, PROs were included in the product label. For payers, utility values based 
on PROs were used in cost-effectiveness evaluations for three of the six products. 
For the manufacturer, the PRO data generated label claims and many publications 
that allowed extensive public dissemination of product benefits. CONCLUSIONS: 
Patient-reported assessment of the treatment impact on disease during drug devel-
opment has many benefits for all stakeholders.
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OBJECTIVES: A draft patient-reported outcome measure for psoriasis treatment 
(PROMPT) was developed through patient interviews and comprised 91 items 
across seven core domains. This study aimed to evaluate the scaling proper-
ties and construct validity of the draft measure using the Rasch measurement 
model. METHODS: Patients with chronic plaque psoriasis were identified and 
recruited according to pre-defined inclusion and exclusion criteria through pso-
riasis-specific secondary care clinics in the United Kingdom and two national 
patient organizations. Patients completed the draft measure at two time points, 14 
days apart. Respondents with ≥ 40% of missing data were removed from the final 
analyses. Data from each sub-scale were analyzed separately using RUMM2030 
software to explore Rasch model fit, item difficulty, local dependence, item cat-
egory thresholds, and differential item functioning (DIF) by age and gender. Where 
necessary, items were removed individually and the scale iteratively reassessed 
for fit and unidimensionality. RESULTS: A sample of n= 209 patients with chronic 
plaque psoriasis completed the draft measure. Initial fit to the model was poor; 
disordered category thresholds were identified for items in all scales. Post-hocre-
scoring from a 5-point Likert scale to a 3-point Likert scale improved model fit. 
Items which showed local dependence were removed in context of qualitative 
findings. Following removal of 11 items, all 7 scales demonstrated acceptable fit 
with the Rasch model (Chi Sq = 0.09 to 0.2) There was no evidence of DIF by age 
and gender. CONCLUSIONS: The new measure, PROMPT, comprised 80 items in 6 
independent, unidimensional scales, free from age or gender bias, with acceptable 
fit to the Rasch model. As such, the measure is considered to show initial promise 
for use with patients with chronic plaque psoriasis in a clinical setting. The psy-
chometric properties and scoring of the measure should be explored further and 
confirmed in future studies.
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score distributions and indices of reliability and validity. RESULTS: The literature 
review and input from patients indicates that HS is associated with a range of 
symptoms (e.g., pain, drainage, itchiness) and impacts (e.g., difficulty with move-
ment and interference with sexual activities). These concepts were organized into 
a conceptual model to facilitate the construction of the questionnaires. Results 
from the cognitive interviews indicated that both the HSSA and HSIA are easily 
understood by patients and characterize their condition well. Forty subjects com-
pleted the observational study (females = 58%; Caucasian = 65%; and age [mean] = 
41 years). The HSIA and HSSA scores were found to perform well psychometrically, 
with strong evidence of test-retest (ICC= 0.92 and 0.80, respectively) and internal 
consistency (α = 0.97 and 0.96, respectively) reliability and known groups (P< 0.001 
and P< 0.006, respectively) and construct-related validity (via correlations between 
the target measures and other, concurrently administered tools). CONCLUSIONS: 
There is robust evidence supporting the HSIA and HSSA as content valid and 
psychometrically sound questionnaires for assessing symptoms and impacts in 
patients with HS.
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OBJECTIVES: Visual acuity does not fully capture the effect of geographic atro-
phy (GA), secondary to age-related macular degeneration, on visual function. The 
Functional Reading Independence (FRI) Index is a 7-item patient-reported measure 
developed for use in GA trials. This study examined the sensitivity of the FRI Index 
to change in GA lesion size. METHODS: Post hoc analyses were conducted with data 
from MAHALO, a phase 2 study of lampalizumab, a complement factor monoclonal 
antibody fragment, for treatment of GA. For each reading activity performed in the 
past 7 days (e.g., writing checks or reading medicine labels), patients were asked the 
extent to which they required vision aids, adjustments in the activity, or help from 
another person. The FRI Index yields continuous mean scores (range 1-4) and ordinal 
level scores (from Level 1= Unable to do to Level 4= Totally Independent). Analysis 
of covariance compared mean changes in FRI Index scores stratified by more 
(≥ 0.94mm2/yr) vs less (< 0.94mm2/yr) GA lesion growth. RESULTS: At 18 months, the 
mean change in FRI Index score (SD) from baseline for patients with more lesion size 
growth was -0.3 (0.5; n= 13) vs -0.1 (0.7; n= 62) for patients with less growth (P= 0.02). 
For patients with more growth, 36% declined ≥ 1 FRI Level vs 15% for less growth. 
Excluding patients at FRI Level 1 at baseline, 41% of patients with more growth 
(N= 54) declined > 1 FRI Level vs 18% with less growth (N= 11). CONCLUSIONS: In 
MAHALO, the change in mean FRI Index score of 0.2 differentiated patients with 
more vs less growth of GA lesion size. FRI level scores were also sensitive to GA 
lesion growth. These results provide evidence that patient-reported functional read-
ing independence as measured by the FRI Index is linked to GA lesion growth, an 
objective clinical measure of disease progression.
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OBJECTIVES: Translation and linguistic validation of patient reported outcomes (PRO) 
measures is an essential component of research methodology in preparation for mul-
tinational research studies. The Urticaria Activity and Impact Measure (U-AIM) is a dis-
ease specific tool developed in English to assess the impact of chronic urticaria from 
the patient’s viewpoint. The objective of this work was to translate and linguistically 
validate the U-AIM from English to Spanish for use in the US. METHODS: The U-AIM 
was translated into universal Spanish according to industry standard methodology. 
After the translation was completed, five Spanish-speaking patients in the US diag-
nosed with chronic idiopathic urticaria completed the translated questionnaire and 
participated in a cognitive debriefing interview. Interviews were conducted using a 
standardized guide to assess the relevance, understandability, and appropriateness of 
the translations. Qualitative analyses were performed to ensure equivalence and that 
the content validity of the U-AIM was maintained for the Spanish version. RESULTS: 
Of the five patients (40% male), the mean age of four was 37 years [one patient did 
not report his age]. All U-AIM items were well understood and proved relevant to the 
patients in this sample. Of interest, terms such as, “urticaria,” “hives,” “angioedema” 
and “rapid swelling” were clearly understood as intended. CONCLUSIONS: The results 
indicate that the Spanish version of the U-AIM translation is conceptually equivalent 
to the English source version and easily understood by the target population in the US. 
We consider the translation to be acceptable for PRO assessment in research and clini-
cal practice. Future research could include testing of the questionnaire with patients 
in other Spanish-speaking countries to confirm its acceptability beyond the US.
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OBJECTIVES: Patient reported outcomes (PRO) are becoming useful tools for collecting 
and generating evidence for new medical products to show improvements in health-
related quality of life (HRQoL). Glaucoma is a chronic disease with high importance 
for patient HRQoL. The objective of this study was to review, analyze, and understand 
trends in the PRO instruments used in patients with Glaucoma. METHODS: A sys-
tematic literature search for Glaucoma trials with PROs endpoints was undertaken 
